Latest news
Standard BioTools Q2 2026 Earnings: Cost Cuts Narrow the Adjusted EBITDA Loss - TradingKeyTradingKey · Wed, 05 Aug 2026 21:06:57 GMTSTANDARD BIOTOOLS INC. Q2 2026: Revenue $20.1M, EPS $(0.07) — 10-Q Summary - TradingViewTradingView · Wed, 05 Aug 2026 20:26:35 GMTStandard BioTools Reports Second Quarter 2026 Financial Results - The Manila TimesThe Manila Times · Wed, 05 Aug 2026 20:09:04 GMTStandard BioTools Sells Mass Cytometry Business and Secures $30 Million Illumina Buyout Ahead of Treeline Merger - citybizcitybiz · Tue, 28 Jul 2026 12:32:40 GMTStandard BioTools (NASDAQ: LAB) nets $30M Illumina buyout, sells mass cytometry arm - Stock TitanStock Titan · Tue, 28 Jul 2026 12:25:42 GMTStandard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences - SahmSahm · Tue, 28 Jul 2026 07:00:00 GMTStandard BioTools sells Mass Cytometry business and secures $30M from Illumina earnout buyout - PluangPluang · Tue, 28 Jul 2026 07:00:00 GMTWeekly Recap: Nasdaq non‑compliance notice and S‑4 merger filing - TradingViewTradingView · Mon, 27 Jul 2026 07:00:00 GMT